This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://linked.opendata.cz/resource/drugbank/drug/DB08824/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08824/identifier/chebi/
n11http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB08824/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n12http://www.drugs.com/mtm/
n8http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB08824/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB08824/identifier/drugbank/
n7http://www.pdrhealth.com/info/v1us/

Statements

Subject Item
n2:DB08824
rdf:type
n3:Drug
n3:description
Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.
n3:dosage
n5:271B5736-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Tolosa E, Borght TV, Moreno E: Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007 Dec;22(16):2346-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17914722 # Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000 May;15(3):503-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10830416 # http://md.gehealthcare.com/files/pdfs/msds/datscan.pdf
n3:group
approved
n3:halfLife
Half life is 13.2 hours.
n3:indication
Ioflupane I-123 is a SPECT (single photon emission computerized tomography) agent used to distinguish between Parkinson’s syndrome tremors and essential tremor.
owl:sameAs
n11:DB08824
dcterms:title
Ioflupane I 123
adms:identifier
n14:DB08824 n15:D10014 n16:68855 n17:17156-210-01 n18:Ioflupane
n3:mechanismOfAction
Iodine-123 labeled ioflupane binds to presynaptic dopamine transporters. When Iodine-123 decays, a gammay ray is emmitted and detected through SPECT.
n3:patent
n8:5310912
n3:routeOfElimination
About 60% is excreted in the urine and 14% in the feces after 48 hours.
n3:synonym
methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-[4-((123)I)iodophenyl]-8-azabicyclo[3.2.1]octane-2-carboxylate ioflupane I(123) Datscan ioflupane (123I) Methyl 8-(3-fluoropropyl)-3β-(p-iodo-I(sup 123)-phenyl)-1αH, 5αH-nortropane-2β-carboxylate. ioflupano (123I) 123I-Ioflupane Ioflupane 123I-FP-CIT ioflupanum (123I) ioflupane ((123)I)
n3:volumeOfDistribution
Compared to the entire brain, about 30% of radioactivity is taken up by the striatum.
n3:foodInteraction
No known food interactions.
foaf:page
n7:ioflupane n12:ioflupane-i-123.html
n3:IUPAC-Name
n4:271B573B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5741-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5740-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B573D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B573E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B573F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5750-363D-11E5-9242-09173F13E4C5 n4:271B5739-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5737-363D-11E5-9242-09173F13E4C5 n4:271B573A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5738-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5747-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5748-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5742-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5743-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5745-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5744-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5746-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption is 100% because administered I.V.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
155798-07-5
n3:category
n3:Bioavailability
n4:271B574C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B574E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B574F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5751-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B574B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B574A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B574D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B573C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5749-363D-11E5-9242-09173F13E4C5